论文部分内容阅读
Ｔｅｉｃｏｐｌａｍｉｎ为一种新的糖肽类抗生素。本文报道ｔｅｉｃｏｐｌａｎｉｎ对临床检验的１６５株革兰氏阳性球菌，包括甲氧西林敏感及耐药金黄色葡萄球菌（ＭＳＳＡ、ＭＲＳＡ）、肺炎球菌、粪链球菌和草绿色链球菌的体外抗菌活性，并与去甲万古霉素等抗菌剂比较。结果显示，ｔｅｉｃｏｐｌａｎｉｎ对ＭＲＳＡＭＳＳＡ、肺炎球菌和草绿色链球菌有强的抗菌活性，ＭＩＣ＿（９０）≤２ｍｇ／Ｌ，抑菌率为９５～１００％，对ＭＲＳＥ和ＭＳＳＥ的抗菌率为７１．４％和８２．６％。但对粪链球菌的ＭＩＣ＿（９０）为６４ｍｇ／Ｌ，抑菌率为５８．３％。
Teicoplamin is a new glycopeptide antibiotic. This article reports the in vitro antibacterial activity of teicoplanin against 165 Gram-positive cocci, including methicillin-resistant and resistant Staphylococcus aureus (MSSA, MRSA), pneumococcus, Streptococcus faecalis, and Streptococcus viridans, Compared with antimicrobial agents such as norvancomycin. The results showed that teicoplanin had strong antibacterial activity against MRSAMSSA, pneumococcus and Streptococcus viridans, the MIC_ (90) ≤2mg / L, the antibacterial rate was 95 ~ 100%, the antibacterial rate against MRSE and MSSE was 71.4% And 82.6%. However, the MIC_ (90) of Streptococcus faecalis was 64 mg / L and the inhibitory rate was 58.3%.